In vitro activity: AZD2098 is a potent antagonist of CC-chemokine receptor 4 (CCR4) that has been used for asthma research. It was discovered by throughput screen (HTS) of a subset of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs with one of them being AZD2098. It targets CCR4 which is found on immune cells and helps direct cell trafficking of various types of leukocytes.

Kinase Assay: AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research.

Cell Assay: AZD2098 targets CCR4 which is found on immune cells and helps direct cell trafficking of various types of leukocytes.